)
Hyderabad-based biopharmaceutical company Suven Life Sciences Limited (Suven) has secured one product patent from Eurasia and another from Israel corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. The patents are valid through 2029 and 2030 respectively.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these, Suven has a total of 14 patents from Eurasia and three from Israel. These patents are exclusive intellectual property of Suven and have been achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, a company release stated on Monday.
